Cited by 238PI3K/AKT/mTOR signaling in cancerHead and Neck Cancer StudiesMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck

Amornphimoltham, Panomwat, Patel, Vyomesh, Sodhi, Akrit, Nikitakis, Nikolaos G., Sauk, John J., Sausville, Edward A., Molinolo, Alfredo A., Gutkind, J. Silvio·2005·Cancer Research

DOI 10.1158/0008-5472.can-05-0921

Open this paper in CoChat — free account

Abstract

Emerging knowledge on how the dysregulated function of signaling networks contributes to the malignant growth of squamous cell carcinoma of the head and neck (HNSCC) can now be exploited to identify novel mechanism-based anticancer treatments. In this regard, we have observed that persistent activation of the serine/threonine kinase Akt is a frequent event in HNSCC, and that blockade of its upstream kinase, 3'-phosphoinositide-dependent kinase 1, potently inhibits tumor cell growth. Akt promotes cell proliferation by its ability to coordinate mitogenic signaling with energy- and nutrient-sensing pathways that control protein synthesis through the atypical serine/threonine kinase, mammalian target of rapamycin (mTOR). This kinase, in turn, phosphorylates key eukaryotic translation regulators, including p70-S6 kinase and the eukaryotic translation initiation factor, 4E binding protein 1. Indeed, we show here that aberrant accumulation of the phosphorylated active form of S6, the most downstream target of the Akt-mTOR-p70-S6 kinase pathway, is a frequent event in clinical specimens from patients with HNSCC and their derived cell lines. Of interest, this enhanced level of the phosphorylated active form of S6 was rapidly reduced in HNSCC cell lines and HNSCC xenograft models at clinically relevant doses of rapamycin, which specifically inhibits mTOR. Furthermore, we observed that rapamycin displays a potent antitumor effect in vivo, as it inhibits DNA synthesis and induces the apoptotic death of HNSCC cells, ultimately resulting in tumor regression. These findings identify the Akt-mTOR pathway as a potential therapeutic target for HNSCC, and may provide the rationale for the early clinical evaluation of rapamycin and its analogues in patients with HNSCC.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-05-0921

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., Reddy, H., Caivano, M., & Cohen, P. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510095 · Cited by 4,366
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,248
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
Guba, M. O., von Breitenbuch, P., Steinbauer, M. G. M., Koehl, G. E., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S. A., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Head and Neck Cancer
Forastiere, A. A., Koch, W. M., Trotti, A., & Sidransky, D. (2001) · New England Journal of Medicine · doi:10.1056/nejmra001375 · Cited by 1,262

Show all 63 references

Sorted by citations

Targeted Killing of Cancer Cellsin Vivoandin Vitrowith EGF-Directed Carbon Nanotube-Based Drug Delivery
Bhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 852
Self-citation
Dysregulated molecular networks in head and neck carcinogenesis
Molinolo, A., Amornphimoltham, P., SQUARIZE, C. H., CASTILHO, R. M., Patel, V., & Gutkind, J. S. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2008.07.011 · Cited by 387
Self-citation
mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis
Iglesias-Bartolome, R., Patel, V., Cotrim, A., Leelahavanichkul, K., Molinolo, A. A., Mitchell, J. B., & Gutkind, J. S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.06.007 · Cited by 284
Self-citation
Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative
Molinolo, A. A., Hewitt, S. M., Amornphimoltham, P., Keelawat, S., Rangdaeng, S., Meneses García, A., Raimondi, A. R., Jufe, R., Itoiz, M., Gao, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1041 · Cited by 243
Self-citation
Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial
Alberú, J., Pascoe, M. D., Campistol, J. M., Schena, F. P., Rial, M. D. C., Polinsky, M. S., Neylan, J. F., Korth-Bradley, J. M., Goldberg-Alberts, R., & Maller, E. S. (2011) · Transplantation · doi:10.1097/tp.0b013e3182247ae2 · Cited by 224
The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies
Martı́n, D., Abba, M. C., Molinolo, A., Vitale-Cross, L. A., Wang, Z., Zaida, M., Delic, N. C., Samuels, Y., Lyons, J. G., & Gutkind, J. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2417 · Cited by 206
Self-citation
Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression
Patel, V., Hood, B. L., Molinolo, A., Lee, N. H., Conrads, T. P., Braisted, J. C., Krizman, D. B., Veenstra, T. D., & Gutkind, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1497 · Cited by 192
Self-citation
Glycogen synthase kinase 3 beta: can it be a target for oral cancer
Mishra, R. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-144 · Cited by 192
EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
Freudlsperger, C., Burnett, J. R., Friedman, J., Kannabiran, V. R., Chen, Z., & Waes, C. V. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.541440 · Cited by 183
Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma
Yang, Y., Chen, D., Liu, H., & Yang, K. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1280-8 · Cited by 183
Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: Involvement of the Akt–mTOR signaling pathway
Zhao, Z., Han, F., Yang, S., Wu, J.-H., & Zhan, W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.046 · Cited by 191
Molecular Cross-Talk between the NFκB and STAT3 Signaling Pathways in Head and Neck Squamous Cell Carcinoma
SQUARIZE, C. H., CASTILHO, R. M., Sriuranpong, V., Júnior, D. D. S. P., & Gutkind, J. S. (2006) · Neoplasia · doi:10.1593/neo.06274 · Cited by 176
Self-citation
mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas
Molinolo, A., Marsh, C. A., Dinali, M. E., Gangane, N., Jennison, K., Hewitt, S. M., Patel, V., Seiwert, T. Y., & Gutkind, J. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2824 · Cited by 175
Self-citation
The PI 3 K / A kt/m TOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies
Broek, R. V., Mohan, S., Eytan, D. F., Chen, Z., & Waes, C. V. (2013) · Oral Diseases · doi:10.1111/odi.12206 · Cited by 159
Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis
Kobayashi, S., Kishimoto, T., Kamata, S., Otsuka, M., Miyazaki, M., & Ishikura, H. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00439.x · Cited by 157
Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer
Patel, V., Marsh, C. A., Dorsam, R. T., Mikelis, C. M., Masedunskas, A., Amornphimoltham, P., Nathan, C. O., Singh, B., Weigert, R., Molinolo, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3192 · Cited by 144
Self-citation
Metformin Prevents the Development of Oral Squamous Cell Carcinomas from Carcinogen-Induced Premalignant Lesions
Vitale-Cross, L. A., Molinolo, A., Martín, D., Younis, R. H., Maruyama, T., Patel, V., Chen, W., Schneider, A., & Gutkind, J. S. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0502 · Cited by 145
Self-citation
Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model
Czerninski, R., Amornphimoltham, P., Patel, V., Molinolo, A. A., & Gutkind, J. S. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0147 · Cited by 140
Self-citation
An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR
Hou, G., Xue, L., Lu, Z., Fan, T., Tian, F., & Xue, Y. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.01.026 · Cited by 133
Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular Targets
Iglesias‐Bartolomé, R., Martı́n, D., & Gutkind, J. S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0239 · Cited by 117
Self-citation
Tipifarnib as a Precision Therapy for HRAS -Mutant Head and Neck Squamous Cell Carcinomas
Gilardi, M., Wang, Z., Proietto, M., Chillà, A., Calleja-Valera, J. L., Goto, Y., Vanoni, M., Janes, M. R., Mikulski, Z., Gualberto, A., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0958 · Cited by 115
Self-citation
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model
Sun, Z., Zhang, L., Hall, B., Bian, Y., Gutkind, J. S., & Kulkarni, A. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1371 · Cited by 112
Self-citation
Anti-Tumor Effects of Ganoderma lucidum (Reishi) in Inflammatory Breast Cancer in In Vivo and In Vitro Models
Suárez-Arroyo, I. J., Rosario-Acevedo, R., Aguilar‐Perez, A., Clemente, P. L., Cubano, L. A., Serrano, J., Schneider, R. J., & Martínez, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057431 · Cited by 111
The Molecular Pathogenesis of Head and Neck Cancer
Klein, J. D., & Grandis, J. R. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.1.10905 · Cited by 110
Hypoxia-Induced Energy Stress Inhibits the mTOR Pathway by Activating an AMPK/REDD1 Signaling Axis in Head and Neck Squamous Cell Carcinoma
Schneider, A., Younis, R. H., & Gutkind, J. S. (2008) · Neoplasia · doi:10.1593/neo.08586 · Cited by 107
Self-citation
mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
Wang, Z., Martı́n, D., Molinolo, A., Patel, V., Iglesias‐Bartolomé, R., Degese, M. S., Vitale-Cross, L. A., Chen, Q., & Gutkind, J. S. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju215 · Cited by 106
Self-citation
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase
Szabo, R., Rasmussen, A. L., Moyer, A. B., Kosa, P. F., Schafer, J. M., Molinolo, A., Gutkind, J. S., & Bugge, T. H. (2011) · Oncogene · doi:10.1038/onc.2010.586 · Cited by 105
Self-citation
Mammalian Target of Rapamycin Inhibitors as Possible Adjuvant Therapy for Microscopic Residual Disease in Head and Neck Squamous Cell Cancer
Nathan, C. O., Amirghahari, N., Rong, X., Giordano, T., Sibley, D. A., Nordberg, M. L., Glass, J., Agarwal, A., & Caldito, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2449 · Cited by 104
Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin
SQUARIZE, C. H., CASTILHO, R. M., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0922 · Cited by 103
Self-citation
Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma
Chakraborty, S., Mohiyuddin, S. M. A., Gopinath, K., & Kumar, A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-163 · Cited by 100
Molecular markers associated with development and progression of potentially premalignant oral epithelial lesions: Current knowledge and future implications
Nikitakis, N. G., Pentenero, M., Georgaki, M., Poh, C. F.-Y., Peterson, D. E., Edwards, P. C., Lingen, M. W., & Sauk, J. J. (2018) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2018.03.012 · Cited by 98
Self-citation
Current and potential inflammation targeted therapies in head and neck cancer
Wang, F., Arun, P., Friedman, J., Chen, Z., & Waes, C. V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.005 · Cited by 98
Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion
Patel, V., Rosenfeldt, H. M., Lyons, R., Servitja, J., Bustelo, X. R., Siroff, M., & Gutkind, J. S. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm008 · Cited by 97
Self-citation
Targeted therapy in head and neck cancer
Kundu, S., & Nestor, M. (2012) · Tumor Biology · doi:10.1007/s13277-012-0350-2 · Cited by 95
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Day, T. A., Shirai, K., O’Brien, P. E., Matheus, M. G., Godwin, K., Sood, A. J., Kompelli, A. R., Vick, J. A., Martı́n, D., Vitale-Cross, L. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2024 · Cited by 89
Self-citation
Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K- ras and p53 Two-Hit Carcinogenesis Model
Raimondi, A. R., Molinolo, A., & Gutkind, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4645 · Cited by 88
Self-citation
PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Herzog, A., Bian, Y., Broek, R. V., Hall, B., Coupar, J. F., Cheng, H. W., Sowers, A. L., Cook, J. D., Mitchell, J. B., Chen, Z., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2716 · Cited by 83
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
Massarelli, E., Lin, H. Y., Ginsberg, L. E., Tran, H. T., Lee, J. J., Canales, J. R., Williams, M. D., Blumenschein, G. R., Lu, C. S., Heymach, J. V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv194 · Cited by 85
Molecular Biology of Head and Neck Cancer: Risks and Pathways
Stadler, M., Patel, M. R., Couch, M. E., & Hayes, D. N. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.08.007 · Cited by 83
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
Jimeno, A., Kulesza, P., Wheelhouse, J., Chan, A., Zhang, X., Kincaid, E., Chen, A. R., Clark, D. P., Forastiere, A. A., & Hidalgo, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603656 · Cited by 83
4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Wang, Z., Feng, X., Molinolo, A., Martı́n, D., Vitale-Cross, L. A., Nohata, N., Ando, M., Wahba, A., Amornphimoltham, P., Wu, X., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1220 · Cited by 84
Self-citation
A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Mazumdar, T., Byers, L. A., Ng, P. K. S., Mills, G. B., Peng, S., Diao, L., Fan, Y.-H., Stemke‐Hale, K., Heymach, J. V., Myers, J. N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1090 · Cited by 79
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
Jung, K., Kang, H., & Mehra, R. (2018) · Cancers of the Head & Neck · doi:10.1186/s41199-018-0030-z · Cited by 78
Rab25 Regulates Invasion and Metastasis in Head and Neck Cancer
Amornphimoltham, P., Rechache, K. A., Thompson, J. L., Masedunskas, A., Leelahavanichkul, K., Patel, V., Molinolo, A., Gutkind, J. S., & Weigert, R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2858 · Cited by 77
Self-citation
Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis
Rho, O., Kim, D. J., Kiguchi, K., & DiGiovanni, J. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20665 · Cited by 78
Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
Ekshyyan, O. Y., Rong, Y., Rong, X., Pattani, K. M., Abreo, F. W., Caldito, G. C., Chang, J. K. S., Ampil, F. L., Glass, J., & Nathan, C. O. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1184 · Cited by 76
mTOR co-targeting strategies for head and neck cancer therapy
Wang, Z., Valera, J. L. C., Zhao, X., Chen, Q., & Gutkind, J. S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9688-7 · Cited by 79
Self-citation
Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human Neoplasia
Bugelski, P. J., Volk, A. L., Walker, M., Krayer, J., Martin, P. L., & Descotes, J. (2010) · International Journal of Toxicology · doi:10.1177/1091581810374654 · Cited by 77
The Oncogenic RNA-Binding Protein Musashi1 Is Regulated by HuR via mRNA Translation and Stability in Glioblastoma Cells
Vo, D. T., Abdelmohsen, K., Martindale, J. L., Qiao, M., Tominaga, K., Burton, T. L., Gelfond, J. A. L., Brenner, A. J., Patel, V., Trageser, D., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0208 · Cited by 71
Self-citation
Curcumin Inhibits Carcinogen and Nicotine-Induced Mammalian Target of Rapamycin Pathway Activation in Head and Neck Squamous Cell Carcinoma
Clark, C. A., McEachern, M. D., Shah, S. H., Rong, Y., Rong, X., Smelley, C. L., Caldito, G. C., Abreo, F. W., & Nathan, C. O. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0244 · Cited by 71
Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3
Madera, D., Vitale-Cross, L. A., Martı́n, D., Schneider, A., Molinolo, A., Gangane, N., Carey, T. E., McHugh, J. B., Komarck, C. M., Walline, H. M., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0348 · Cited by 71
Self-citation
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma
Zaryouh, H., Pauw, I. D., Baysal, H., Peeters, M., Vermorken, J. B., Lardon, F., & Wouters, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21806 · Cited by 70
Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
Ghosh, S., Shah, P. A., & Johnson, F. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147889 · Cited by 70
Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery
Xu, L., Yeudall, W. A., & Yang, H. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.04.023 · Cited by 69
MAPK/ERK-Dependent Translation Factor Hyperactivation and Dysregulated Laminin γ2 Expression in Oral Dysplasia and Squamous Cell Carcinoma
Degen, M., Natarajan, E., Barron, P., Widlund, H. R., & Rheinwald, J. G. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.02.028 · Cited by 64
Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt–mTOR signaling pathway in oral squamous cell carcinoma
Kapoor, V., Zaharieva, M. M., Das, S. N., & Berger, M. R. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.12.032 · Cited by 63
Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication
Chaoul, N., Fayolle, C., Desrues, B., Oberkampf, M., Tang, A., Ladant, D., & Leclerc, C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0454 · Cited by 68
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
Geiger, J. L., Bauman, J. E., Gibson, M. K., Gooding, W. E., Varadarajan, P., Kotsakis, A. P., Martı́n, D., Gutkind, J. S., Hedberg, M. L., Grandis, J. R., et al. (2016) · Head & Neck · doi:10.1002/hed.24501 · Cited by 64
Self-citation
Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions
Amornphimoltham, P., Leelahavanichkul, K., Molinolo, A., Patel, V., & Gutkind, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0703 · Cited by 63
Self-citation
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
Erlich, R. B., Kherrouche, Z., Rickwood, D., Endo‐Munoz, L., Cameron, S. R., Dahler, A. L., Hazar-Rethinam, M. H., de Long, L. M., Wooley, K., Guminski, A. D., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.495 · Cited by 62
Inhibition of mTOR Suppresses UVB-Induced Keratinocyte Proliferation and Survival
Carr, T. D., DiGiovanni, J., Lynch, C. J., & Shantz, L. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0272-t · Cited by 62
Akt pathway as a target for therapeutic intervention in HNSCC.
Moral, M., & Paramio, J. M. (2008) · PubMed · doi:10.14670/hh-23.1269 · Cited by 58
Rapamycin Is a Potent Inhibitor of Skin Tumor Promotion by 12- O -Tetradecanoylphorbol-13-Acetate
Checkley, L. A., Rho, O., Moore, T., Hursting, S., & DiGiovanni, J. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0375 · Cited by 60
Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients
Clark, C. A., Shah, S. H., Ferdinandez, L. H., Ekshyyan, O. Y., Abreo, F. W., Rong, X., McLarty, J. W., Lurie, A. A., Milligan, E. J., & Nathan, C. O. (2010) · The Laryngoscope · doi:10.1002/lary.20917 · Cited by 59
Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Jiang, N., Wang, D., Hu, Z., Shin, H. J. C., Qian, G., Rahman, M. A., Zhang, H., Amin, A. R. M. R., Nannapaneni, S., Wang, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1093 · Cited by 61
Precision Therapy of Head and Neck Squamous Cell Carcinoma
Polverini, P. J., D’Silva, N. J., & Lei, Y. L. (2018) · Journal of Dental Research · doi:10.1177/0022034518769645 · Cited by 60
Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling
Broek, R. V., Snow, G. E., Chen, Z., & Waes, C. V. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.10.005 · Cited by 57
SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification
Leopoldino, A. M., SQUARIZE, C. H., Garcia, C. B., Almeida, L. O., Pestana, C. R., Sobral, L. M., Uyemura, S. A., Tajara, E. H., Gutkind, J. S., & Curti, C. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.05.014 · Cited by 56
Self-citation
The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis
Yoshioka, A., Miyata, H., Doki, Y., Yasuda, T., Yamasaki, M., Motoori, M., Okada, K., Matsuyama, J., Makari, Y., Sohma, I., et al. (2008) · Oncology Reports · doi:10.3892/or.19.5.1099 · Cited by 56
Combined Transcriptional and Translational Targeting of EWS/FLI-1 in Ewing's Sarcoma
Mateo‐Lozano, S., Gokhale, P. C., Soldatenkov, V. A., Dritschilo, A., Tirado, Ò. M., & Notario, V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0609 · Cited by 56
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Agulnik, M. (2012) · Medical Oncology · doi:10.1007/s12032-012-0159-2 · Cited by 55
Targeting Antiapoptotic Bcl-2 Family Members with Cell-Permeable BH3 Peptides Induces Apoptosis Signaling, Death in Head, Neck Squamous Cell Carcinoma Cells
Li, R., Boehm, A. L., Miranda, M. B., Shangary, S. K., Grandis, J. R., & Johnson, D. E. (2007) · Neoplasia · doi:10.1593/neo.07394 · Cited by 54
Overexpression and activation of Akt2 protein in oral squamous cell carcinoma
Iamaroon, A., & Krisanaprakornkit, S. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.06.003 · Cited by 50
Single-center experience with sirolimus therapy for vascular malformations
Yeşil, Ş., Tanyıldız, H. G., Bozkurt, C., Çakmakçı, E., & Şahin, G. (2016) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2016.1160170 · Cited by 49
mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
Hou, G., Zhang, Q., Wang, L., Liu, M., Wang, J., & Xue, L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.015 · Cited by 47
Rapamycin Inhibits Anal Carcinogenesis in Two Preclinical Animal Models
Stelzer, M. K., Pitot, H. C., Liem, A., Lee, D., Kennedy, G. D., & Lambert, P. F. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0228 · Cited by 47
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
Mehra, R. (2010) · Biologics · doi:10.2147/btt.s3050 · Cited by 46
A Retroinhibition Approach Reveals a Tumor Cell–Autonomous Response to Rapamycin in Head and Neck Cancer
Amornphimoltham, P., Patel, V., Leelahavanichkul, K., Abraham, R. T., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1756 · Cited by 45
Self-citation
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Dunn, L. A., Fury, M. G., Xiao, H., Baxi, S. S., Sherman, E. J., Korte, S. H., Pfister, C., Haque, S. S., Katabi, N., Ho, A. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx346 · Cited by 46
Recurrent head and neck cancer: current treatment and future prospects
Specenier, P. M., & Vermorken, J. B. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.3.375 · Cited by 46
Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Rival‐Tringali, A. L., Euvrard, S., Decullier, É., Claudy, A., Faure, M., & Kanitakis, J. (2009) · PubMed · Cited by 45
Grape seed extract and resveratrol prevent 4‐nitroquinoline 1‐oxide induced oral tumorigenesis in mice by modulating AMPK activation and associated biological responses
Shrotriya, S., Tyagi, A., Deep, G., Orlicky, D. J., Wisell, J. A., Wang, X., Sclafani, R. A., Agarwal, R., & Agarwal, C. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22099 · Cited by 46
PI 3K– AKT – mTOR pathway proteins are differently expressed in oral carcinogenesis
Martins, F., de Sousa, S.-C., dos Santos, E., Woo, S., & Gallottini, M. H. C. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12440 · Cited by 44
GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway
Xie, J., Li, Q., Ding, X., & Gao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15135 · Cited by 44
Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-κB activity in human oral squamous cell carcinoma cells
Tamatani, T., Azuma, M., Motegi, K., Takamaru, N., Kawashima, Y., & Bando, T. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.4.761 · Cited by 43
Improved Clearance during Treatment of HPV-Positive Head and Neck Cancer through mTOR Inhibition
Coppock, J. D., Wieking, B. G., Molinolo, A., Gutkind, J. S., Miskimins, W. K., & Lee, J. H. (2013) · Neoplasia · doi:10.1593/neo.13432 · Cited by 43
Self-citation
Molecular targeted therapy of head and neck cancer: Review and clinical development challenges
Tourneau, C. L., Faivre, S. J., & Siu, L. L. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.016 · Cited by 43
The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways
Kinoshita, T., Hanazawa, T., Nohata, N., Okamoto, Y., & Seki, N. (2012) · Journal of Human Genetics · doi:10.1038/jhg.2012.75 · Cited by 41
Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets
Sandulache, V. C., & Myers, J. N. (2011) · Head & Neck · doi:10.1002/hed.21664 · Cited by 38
Hypoxia-inducible factor-1α polymorphisms and TSC1/2 mutations are complementary in head and neck cancers
HEBERT, C. A., Norris, K., Parashar, P., Ord, R. A., Nikitakis, N. G., & Sauk, J. J. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-3 · Cited by 39
Self-citation
Divide and conquer: two stem cell populations in squamous epithelia, reserves and the active duty forces
Dunaway, S., Rothaus, A., Zhang, Y., Kadekaro, A. L., Andl, T., & Andl, C. D. (2019) · International Journal of Oral Science · doi:10.1038/s41368-019-0061-2 · Cited by 40
Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs)
Asgari, M. M., Arron, S. T., Warton, E. M., Quesenberry, C. P., & Weisshaar, D. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.029 · Cited by 37
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
Fury, M. G., Sherman, E. J., Ho, A. L., Katabi, N., Sima, C. S., Kelly, K. W., Nwankwo, O., Haque, S. S., & Pfister, D. G. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1894-y · Cited by 37
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines
Lattanzio, L., Tonissi, F., Monteverde, M., Vivenza, D., Russi, E. G., Milano, G. A., Merlano, M. C., & Nigro, C. L. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0210-1 · Cited by 37
Benzyl Isothiocyanate Inhibits HNSCC Cell Migration and Invasion, and Sensitizes HNSCC Cells to Cisplatin
Wolf, M. A., & Claudio, P. P. (2014) · Nutrition and Cancer · doi:10.1080/01635581.2014.868912 · Cited by 37
The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro
Li, Q., Song, X., Ji, Y., Jiang, H., & Lingen, X. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.130 · Cited by 36
Differential expression of organic cation transporter OCT ‐3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin
Patel, H. Y., Younis, R. H., Ord, R. A., Basile, J. R., & Schneider, A. (2012) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2012.01196.x · Cited by 35
The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab–bevacizumab–irradiation combination on head and neck cancer xenografts
Bozec, A., Étienne-Grimaldi, M.-C., Fischel, J., Sudaka, A., Toussan, N., Formento, P., & Milano, G. A. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.02.020 · Cited by 35
Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer
Izumi, H., Wang, Z., Goto, Y., Ando, T., Wu, X., Zhang, X., Li, H., Johnson, D. E., Grandis, J. R., & Gutkind, J. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1036 · Cited by 33
Self-citation
Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications
Schmitz, S., & Machiels, J. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.115 · Cited by 34

Authors: Amornphimoltham, P., Patel, V., Sodhi, A., Nikitakis, N. G., Sauk, J. J., Sausville, E. A., Molinolo, A. A., & Gutkind, J. S.
Affiliations: National Institutes of Health (US)
University of Maryland, Baltimore (US)
ORCID: Amornphimoltham, Panomwat
Sodhi, Akrit
Sauk, John J.
Molinolo, Alfredo A.
Gutkind, J. Silvio
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2005-11-01
Volume: 65
Issue: 21
Pages: 9953-9961
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-05-0921
OpenAlex: W2115100370
Cited by: 238
References: 63
Citations by year: 2026: 1 · 2025: 2 · 2024: 7 · 2023: 14 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 7 · 2017: 10 · 2016: 20 · 2015: 14 · 2014: 14 · 2013: 13 · 2012: 27
FWCI: 4.11
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: mammalian target of rapamycin, mTOR, head and neck squamous cell carcinoma, Akt signaling, p70 S6 kinase, 4E-binding protein 1, rapamycin, PI3K/AKT/mTOR pathway, translational regulation, apoptosis, cancer therapy, 3-phosphoinositide-dependent kinase 1
MeSH terms: Animals, Antibiotics, Antineoplastic, Carcinoma, Squamous Cell, DNA, Neoplasm, Female, Head and Neck Neoplasms, Humans, Mice, Nude, Phosphorylation, Protein Kinases, Signal Transduction, Apoptosis, Phosphatidylinositol 3-Kinases, Sirolimus, Xenograft Model Antitumor Assays, Ribosomal Protein S6 Kinases, 70-kDa, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks